Page 123 - 2022_03-Haematologica-web

O-linked glycans protect VWF
Willebrand factor in the rat. Blood.
1996;88(5):1692-1699.
29. O'Sullivan JM, Aguila S, McRae E, et al. N-
linked glycan truncation causes enhanced clearance of plasma-derived von Willebrand factor. J Thromb Haemost. 2016;14(12): 2446-2457.
30. Preston RJ, Rawley O, Gleeson EM, O'Donnell JS. Elucidating the role of carbo- hydrate determinants in regulating hemosta- sis: insights and opportunities. Blood. 2013;121(19):3801-3810.
31. Gallinaro L, Cattini MG, Sztukowska M, et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood. 2008;111(7):3540- 3545.
32. Ward SE, O'Sullivan JM, O'Donnell JS. The relationship between ABO blood group, von Willebrand factor, and primary hemostasis. Blood. 2020;136(25):2864-2874.
33. Ellies LG, Ditto D, Levy GG, et al. Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by con- cealing asialoglycoprotein receptor ligands. Proc Natl Acad Sci U S A. 2002;99(15): 10042-10047.
34. Canis K, McKinnon TA, Nowak A, et al. Mapping the N-glycome of human von Willebrand factor. Biochem J. 2012;447(2): 217-228.
35. Canis K, McKinnon TA, Nowak A, et al. The plasma von Willebrand factor O-glycome comprises a surprising variety of structures including ABH antigens and disialosyl motifs. J Thromb Haemost. 2010;8(1):137- 145.
36. Solecka BA, Weise C, Laffan MA, Kannicht C. Site-specific analysis of von Willebrand factor O-glycosylation. J Thromb Haemost. 2016;14(4):733-746.
37. Gashash EA, Aloor A, Li D, et al. An Insight into glyco-microheterogeneity of plasma von Willebrand factor by mass spectrome- try. J Proteome Res. 2017;16(9):3348-3362.
38. Yang WH, Aziz PV, Heithoff DM, Mahan MJ, Smith JW, Marth JD. An intrinsic mech- anism of secreted protein aging and
39.
40.
41.
42.
43.
44.
45.
turnover. Proc Natl Acad Sci U S A. 2015;112(44):13657-13662.
Lopes AA, Ferraz de Souza B, Maeda NY. Decreased sialic acid content of plasma von Willebrand factor in precapillary pulmonary hypertension. Thromb Haemost. 2000;83 (5):683-687.
van Schooten CJ, Denis CV, Lisman T, et al. Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels. Blood. 2007;109(6):2430-2437.
Ward S, O'Sullivan JM, O'Donnell JS. von Willebrand factor sialylation-A critical regu- lator of biological function. J Thromb Haemost. 2019;17(7):1018-1029.
Millar CM, Riddell AF, Brown SA, et al. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of gly- cosylation, proteolysis and gene mutations. Thromb Haemost. 2008;99(5):916-924. McGrath RT, van den Biggelaar M, Byrne B, et al. Altered glycosylation of platelet- derived von Willebrand factor confers resist- ance to ADAMTS13 proteolysis. Blood. 2013;122(25):4107-4110.
McGrath RT, McKinnon TA, Byrne B, et al. Expression of terminal alpha2-6-linked sialic acid on von Willebrand factor specifically enhances proteolysis by ADAMTS13. Blood. 2010;115(13):2666-2673.
Tsuiji M, Fujimori M, Ohashi Y, et al. Molecular cloning and characterization of a novel mouse macrophage C-type lectin, mMGL2, which has a distinct carbohydrate specificity from mMGL1. J Biol Chem. 2002;277(32):28892-28901.
O'Donnell JS. Platelet von Willebrand fac- tor--structure, function and biological importance. Br J Haematol. 2010;148 (6):834-843.
49. Williams SB, McKeown LP, Krutzsch H, Hansmann K, Gralnick HR. Purification and characterization of human platelet von Willebrand factor. Br J Haematol. 1994;88(3): 582-591.
50. Brown SA, Collins PW, Bowen DJ. Heterogeneous detection of A-antigen on von Willebrand factor derived from platelets, endothelial cells and plasma. Thromb Haemost. 2002;87(6):990-996.
51. Lenting PJ, Pegon JN, Christophe OD, Denis CV. Factor VIII and von Willebrand factor-- too sweet for their own good. Haemophilia. 2010;16 Suppl 5:194-199.
52. Tischer A, Machha VR, Moon-Tasson L, Benson LM, Auton M. Glycosylation steri- cally inhibits platelet adhesion to von Willebrand factor without altering intrinsic conformational dynamics. J Thromb Haemost. 2020;18(1):79-90.
53. Deng W, Wang Y, Druzak SA, et al. A dis- continuous autoinhibitory module masks the A1 domain of von Willebrand factor. J Thromb Haemost. 2017;15(9):1867-1877.
54. Soong G, Muir A, Gomez MI, et al. Bacterial neuraminidase facilitates mucosal infection by participating in biofilm production. J Clin Invest. 2006;116(8):2297-2305.
55. Badirou I, Kurdi M, Legendre P, et al. In vivo analysis of the role of O-glycosylations of von Willebrand factor. PLoS One. 2012;7(5): e37508.
56. Saint-Lu N, Oortwijn BD, Pegon JN, et al. Identification of galectin-1 and galectin-3 as novel partners for von Willebrand factor. Arterioscler Thromb Vasc Biol. 2012;32(4): 894-901.
57. O'Sullivan JM, Jenkins PV, Rawley O, et al. Galectin-1 and galectin-3 constitute novel- binding partners for factor VIII. Arterioscler Thromb Vasc Biol. 2016;36(5):855-863.
58. Deppermann C, Kratofil RM, Peiseler M, et al. Macrophage galactose lectin is critical for Kupffer cells to clear aged platelets. J Exp Med. 2020;217(4):e20190723.
46. Wohner N, Legendre P, Casari C, Christophe OD, Lenting PJ, Denis CV. Shear stress-inde- pendent binding of von Willebrand factor- type 2B mutants p.R1306Q & p.V1316M to LRP1 explains their increased clearance. J Thromb Haemost. 2015;13(5):815-820.
47. Mannucci PM. Platelet von Willebrand fac- tor in inherited and acquired bleeding disor- ders. Proc Natl Acad Sci U S A. 1995;92(7): 2428-2432.
48. McGrath RT, McRae E, Smith OP,
haematologica | 2022; 107(3)
679